Word

ANDBODY

Status

Pending

Status Code

688

Status Date

Tuesday, April 23, 2024

Serial Number

97646792

Mark Type

4

Filing Date

Tuesday, October 25, 2022

Published for Opposition

Tuesday, February 27, 2024

Trademark Owner History

AMPERSAND BIOTECHNOLOGIES, INC. - Owner At Publication
Flagship Labs 75, Inc. - Original Applicant

Classifications

5 Biological therapeutics, namely, addressable and programmable protein-based therapeutics, including multi-specific polypeptide-based therapeutics, namely, therapeutic pharmaceuticals for the treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders; pharmaceutical preparations, namely, addressable and programmable protein-based therapeutics, for treatment of genetic diseases and disorders, genomic diseases and disorders, hematological disorders, hormonal disorders, infectious diseases, reproductive disorders, metabolic disorders, orthopedic conditions, musculoskeletal diseases and disorders, gastrointestinal diseases and disorders, immune system-related diseases and disorders, dermatological diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, cancer, diabetes, and respiratory diseases and disorders

1 Biological and chemical agents for scientific use other than for medical use, namely, addressable and programmable protein-based therapeutics

42 Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services

AND BODY

Trademark Events

Nov 8, 2022

New Application Office Supplied Data Entered

May 26, 2023

Assigned To Examiner

May 26, 2023

Non-Final Action Written

May 26, 2023

Non-Final Action E-Mailed

May 26, 2023

Notification Of Non-Final Action E-Mailed

Aug 18, 2023

Teas Response To Office Action Received

Aug 18, 2023

Correspondence Received In Law Office

Aug 19, 2023

Teas/Email Correspondence Entered

Aug 23, 2023

Automatic Update Of Assignment Of Ownership

Oct 4, 2023

Assignment Of Ownership Not Updated Automatically

Oct 24, 2023

Final Refusal Written

Oct 24, 2023

Final Refusal E-Mailed

Oct 24, 2023

Notification Of Final Refusal Emailed

Jan 18, 2024

Teas Request For Reconsideration Received

Jan 18, 2024

Correspondence Received In Law Office

Jan 18, 2024

Teas Change Of Owner Address Received

Jan 18, 2024

Applicant/Correspondence Changes (Non-Responsive) Entered

Jan 18, 2024

Teas Change Of Correspondence Received

Jan 19, 2024

Teas/Email Correspondence Entered

Jan 20, 2024

Approved For Pub - Principal Register

Feb 7, 2024

Notification Of Notice Of Publication E-Mailed

Feb 7, 2024

Official Gazette Publication Confirmation E-Mailed

Feb 27, 2024

Published For Opposition

Mar 4, 2024

Official Gazette Publication Confirmation E-Mailed

Apr 23, 2024

Noa E-Mailed - Sou Required From Applicant